Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2

Melatonin for the delta variant of SARS-CoV-2

  • Russel J Reiter Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, Texas, USA
  • Daniel P Cardinali Faculty of Medical Sciences, Pontifica Universidad Catolica Argentina, Buenos Aires, Argentina
  • Richard L Neel Family Doctor, 1501 Houston Street, Castroville, TX 78009, USA
  • Alberto Dominguez Rodriguez Department of Cardiology, University Hospital o Canary Islands San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
  • Gregory M D Brown Department of Psychiatry, University o Toronto, Toronto, Canada
  • Jan Tesarik MAR & Gen Clinic Granada, Granada, Spain
DOI: https://doi.org/10.32794/mr112500107
Keywords: melatonin, SARS-CoV-19, COVID-19 delta variant, future variants

Abstract

Melatonin was shown to prevent or mitigate a number of different respiratory and non-respiratory viral diseases. Given its non-specific anti-viral action, it is likely to be effective against the delta variant of SARS-CoV-2 as well as any eventual future variants of the virus.


References

1. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ (2020) COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 250: 117583. doi: 10.1016/j.lfs.2020.117583.
2. Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A (2020) Therapeutic algorithm for use of melatonin in patients with COVID-19. Front. Med. (Lausanne). 7: 226. doi: https://doi.org/10.3389/fmed.2020.00226.
3. Tesarik J (2020) Melatonin to reduce death toll due to COVID-19: From innate to adaptive immune response. Glob. J. Med. Res. K Interdisciplinary 20 (8): Version 1.0. doi: 10.34257/gjmrkvol20is8pg5.
4. Cho JH, Bhutani S, Kim CH, Irwin MR (2021) Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials. Brain Behav. Immm. 93: 245-253. doi: 10.1016/j.bbi.2021.01.034.
5. Galano A, Tan DX, Reiter RJ (2018) Melatonin: A versatile protector against oxidative DNA damage. Molecules 23: 530. doi: 10.3390/molecules23030530.
6. Yokota S, Miyamae T, Kuroiwa Y, Nishioka K (2021) Novel coronavirus disease 2019 (COVID-19) and cytokine storms for more effective treatments from an inflammatory pathophysiology. J. Clin. Med. 10: 801. doi: 10.3390/jcm10040801.
7. Mehrzadi S, Karimi MY, Fatemi A, Reiter RJ, Hosseinzadeh A (2021) SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin. Pharmacol. Ther. 224: 107825. doi: 10.1016/j.pharmthera.2021.107825.
8. Zhou Y, Hou Y, Shen J, Mehra R,Kallianpur A, Culver DA, et al. (2020) A network medicine approach to investigation and population-base validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol. 18: e3000970. https://doi.org/10.1371/journal.pbio.3000970.
9. Cardinali DP, Brown GM, Pandi-Perumal SR (2020) Can melatonin be a Potential "silver bullet" in treating COVID-19 patients? Diseases 8: 44. doi: 10.3390/diseases8040044.
10. Magnavita N, Chirico F, Garbarino S, Bragazzi NL, Santacroce E, Zaffina S (2021) SARS/MERS/SARS-CoV-2 outbreaks and burnout syndrome among healthcare workers. An umbrella systematic review. Int. J. Environ. Res. Public Health 18: 4361. doi: 10.3390/ijerph18084361.
11. Tan DX, Hardeland R (2020) Targeting host defense system and rescuing compromised mitochondria to increase tolerance against pathogens by melatonin may impact outcome of deadly virus infection pertinent to COVID-19. Molecules 25: 4410. doi: 10.3390/molecules25194410.
12. Tesarik J (2020) Melatonin attenuates growth factor receptor signaling required for SARS-CoV-2 replication. Melatonin Res. 3: 534-537. doi: 10.32794/mr11250077.
13. Chadha J, Khullar L, Mittal N (2021) Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. Environ. Microbiol. 2021. doi: 10.1111/1462-2920.15687. Epub ahead of print. PMID: 34320263.
14. Bakadia BM, Boni BOO, Ahmed AAQ, Yang G (2021) The impact of oxidative stress damage induced by the environmental stressors on COVID-19. Life Sci. 264: 118653. doi: 10.1016/j.lfs.2020.118653.
15. van Oosterhout C, Hall N, Ly H, Tyler KM (2021) COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence 12: 507-508. doi: 10.1080/21505594.2021.
16. Tanno LK, Castells M, Caminati M, Senna G, Demoly P (2021) Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? Curr. Opin. Allergy Clin. Immunol. 21 (5):411-417. doi: 10.1097/ACI.0000000000000778.
17. Maestroni G (2020) Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines. J. Neuroimmune Pharmacol. 15: 572-573. doi: 10.1007/s11481-020-09956-1.
18. Tesarik J, Reiter RJ (2021) Melatonin as an adjuvant in COVID-19 vaccination. J. SARS-CoV-2 COVID. 2: 009.
19. Wichniak A, Kania A, Siemiński M, Cubała WJ (2021) Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. Int. J. Mol. Sci. 22: 8623. doi: 10.3390/ijms22168623.
20. Zhai X, Wang N, Jiao H, Zhang J, Li C, Ren W, Reiter RJ, Su S (2021) Melatonin and other indoles show antiviral activities against swine coronaviruses in vitro at pharmacological concentrations. J. Pineal Res. 17: e12754. doi: 10.1111/jpi.12754.
21. Brusco LI, Cruz P, Cangas A, Rojas C, Vigo D, Cardinali D (2021) Efficacy of melatonin in non intensive care unit patients with COVID-19 pneumonia and sleep dysregulation. Melatonin Res. 4: 173-188. doi:10.32794/mr11250089.
22. Cardinali DP, Brown GM, Pandi-Perumal SR (2021) Chronotherapy. Handb. Clin. Neurol. 179: 357-370. doi: 10.1016/B978-0-12-819975-6.00023-6.
Published
2021-09-30
How to Cite
[1]
Reiter, R.J., Cardinali, D.P., Neel, R.L., Rodriguez, A.D., Brown, G.M. and Tesarik, J. 2021. Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2. Melatonin Research. 4, 3 (Sep. 2021), 495-500. DOI:https://doi.org/https://doi.org/10.32794/mr112500107.
Issue
Vol 4 No 3 (2021): Melatonin Research
Section
Commentary
DOI
https://doi.org/10.32794/mr112500107
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

For all articles published in Melatonin Res., copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper credit.

In exceptional circumstances articles may be licensed differently. If you have specific condition (such as one linked to funding) that does not allow this license, please mention this to the editorial office of the journal at submission. Exceptions will be granted at the discretion of the publisher.

Most read articles by the same author(s)